Testing effectiveness (Phase 2)Study completedNCT04827745
What this trial is testing
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
Who this might be right for
Mixed Phenotype Acute Leukemia (MPAL)Measurable Residual Disease (MRD)
University of Maryland, Baltimore 2